Pfizer
NEWS
BioSpace’s 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.
In a Phase III trial, Pfizer’s RSVpreF, a bivalent RSV vaccine, protected infants against severe medically attended lower respiratory tract illness when administered during the second or third trimester.
Erasca announced that it was expanding its existing partnership with Pfizer to assess its ERAS-007 in combination with the Big Pharma’s Ibrance.
Backed by Pfizer, Merck KGaA and J&J, Nucleome Therapeutics secured £37.5 million (about $42.16 million) in an oversubscribed Series A financing round.
The FDA has numerous activities and interactions with Phanes, Prestige Biopharma, Reata, Pfizer and more, providing clearance, approving clinical trials and other regulatory actions.
Pfizer and BioNTech released early data Thursday morning from a Phase II/III trial assessing an Omicron-specific booster that showed it provided significant protection, confirming early research.
Biohaven will focus on developing therapeutics that modulate the Kv7 Ion Channel for the treatment of neurological and neuropsychiatric diseases. The new entity launched with $257.8 million in cash.
Funding rounds this week saw money flow into innovative drug discovery and delivery platforms, while pharma powerhouse Pfizer wrapped up two high-value neuro deals.
Early data from the Phase III TALAPRO-2 study showed Talzenna, Pfizer’s oral PARP inhibitor, met its primary endpoint in metastatic castration-resistant prostate cancer patients.
JOBS
IN THE PRESS